New Concept of DSAEK Injecting System. Takeshi Ide, MD,PhD, Terrence P. O’Brien, MD, Sonia H. Yoo, MD Bascom Palmer Eye Institiute, Miami, FL, USA. Financial Disclosure Educational Research Grant was provided by KANEKA(Osaka Japan) Takeshi Ide, MD: research for KANEKA
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Takeshi Ide, MD,PhD, Terrence P. O’Brien, MD, Sonia H. Yoo, MD
Bascom Palmer Eye Institiute, Miami, FL, USA
Educational Research Grant was provided by KANEKA(Osaka Japan)
Takeshi Ide, MD: research for KANEKA
TerrenceO’Brien MD: consultant for AMO, Alcon, Allergan, B&L, Inspire Pharmaceuticals, Ista Pharmaceuticals Sirion Therapeutics, and Vistakon Pharmaceuticals
Sonia Yoo, MD: consultant for Alcon; research for Carl Zeiss Meditec; travel expenses by IntraLase Corpation
None of the authors have a propriety interest in this study.
To report the efficacy and safety of a new DSAEK tissue injecting system in an in vitro experimental model.
Three human DSAEK donor tissues were prepared and loaded into our DSAEK injecting system. The tissues were subsequently injected into balanced salt solution (BSS) and stained with alizarin red S and trypan blue. Imaging software was then utilized to identify and analyze the endothelial cell damage area.
This DSAEK injecting system functioned adequately for all three donor tissues. The cell damage area was 12.98±3.13%, which was comparable or less than reported damage areas by other injecting devices.
This injecting system was as safe as other reported devices with regard to cell damage. This device also can maintain the anterior chamber, inject air, and release pressure. These features could significantly enhance the safety of DSAEK.
To report the efficacy and safety of a new DSAEK tissue injection system in an in vitro experimental model.
New DSAEK Injection System
(A) Injector Bodywith two pushers to insert donor tissues into host eyes( one pusher is for tissue injection and the other for releasing AC pressure)
(B) 1ml-Syringe for injecting air into anterior chamber (AC).
(C) Roller Clamp to control the flow rate of ophthalmic surgical solution
(D) Balanced Salt Solution
(BSS) to maintain AC.
(A) Insert the nozzle part of the injector, irrigate BSS solution to maintain AC
(B) Inject the tissues into the AC
(C) Inject air bubble to lift up the tissues
(D) Reduce IOP to avoid sudden AC collapse and the sudden ejection of the tissues from the AC as a result of the high IOP.
(E) Remove the Injector, and finish tissue insertion.
Sample1 and three different gating conditions
Sample2 and three different gating conditions
Sample3 and three different gating conditions
Quantitative analysis of the acute endothelial cell damage was performed by the method described by Terry et al. *18, 23
Table : Cell Damage Area
Different Gating Conditions by 3 different corneal specialists